A 3‐week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death

• Autores principales: François Briand (Autor), Christophe Heymes (Autor), Lucile Bonada (Autor), Thibault Angles (Autor), Julie Charpentier (Autor), Maxime Branchereau (Autor), Emmanuel Brousseau (Autor), Marjolaine Quinsat (Autor), Nicolas Fazilleau (Autor), Rémy Burcelin (Autor), Thierry Sulpice (Autor)
• Formato: Libro
• Publicado: Wiley, 2020-05-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

The long duration of animal models represents a clear limitation to quickly evaluate the efficacy of drugs targeting nonalcoholic steatohepatitis (NASH). We, therefore, developed a rapid mouse model of liver inflammation (i.e., the mouse fed a high‐fat/high‐cholesterol diet, where cyclodextrin is co...